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Like most solid tumours, the tumorigenesis of nasopharyngeal
carcinoma (NPC) involves accumulation of multiple genetic alter-
ations. Overexpression of several proto-oncogenes Bcl-2, c-Myc
and Ras has been reported in this tumour (Lu et al, 1993; Porter et
al, 1994). Our previous studies demonstrated that frequent allelic
losses at chromosomes 3p, 9p, 11q and 14q were found in
NPC(Huang, 1991, 1994; Hui, 1996; Cheng et al, 1997).
Homozygous deletion in 9p21–22 has been detected both in NPC
primary tumours and xenografts (Huang et al, 1994; Lo et al,
1995). Recent studies have localized three INK4 family genes, p16
(CNKN2A, MTS1, INK4A), p15 (CNKN2B, INK4B) and p19
(ARF) to this affected region (Kamb et al 1994; Hannon and
Beach, 1994; Nobori et al 1994; Chan et al, 1995). Among these
genes, high incidence of p16 gene alterations (77.1%), either due
to homozygous deletion or aberrant methylation resulting in lose
of p16 expression, has been observed in the primary tumours (Lo,
1995; Lo et al, 1996). It is likely that p16 is the primary target for
inactivation in this region. Frequent absence of the p16 protein has
also been reported (Gulley et al, 1998). Detection of high
frequency of altered p16 gene in NPC stands it out as the most
common genetic abnormality found in this cancer.
The progression of a normal cell from G1 into S phase in a cell
cycle is regulated by the cyclin-dependent kinases (cdk) 4/6 and
cyclin D1 complex through phosphorylation of the retinoblastoma
protein (pRb) at the late G1 phase (Hinds et al, 1992; Kato et al,
1993). By competing with cyclin D1 for binding to cdk4/6, the p16
protein inhibits phosphorylation of pRb and arrests cells at the G1
phase. Inactivation of p16 may lead to persistent pRb phosphoryla-
tion and, therefore, resulting uncontrolled cell proliferation.
The current study aimed to investigate the tumour suppressor
role of p16 in NPC. We introduced a wild-type p16 cDNA expres-
sion construct into a p16-deficient NPC cell line NPC/HK-1 and
examined for growth and tumorigenic parameters of the resultant
transfected cells. Our data demonstrated that restoration of p16
expression in NPC/HK1 cells suppressed growth by arresting cells
at G1 phase and inhibited tumorigenicity in athymic nude mice.
MATERIALS AND METHODS
Cell line and transfection
The human cell line NPC/HK-1 was derived from a well-differen-
tiated NPC tumour (Huang et al, 1980). No p16 protein is found in
this cell line as one allele of the p16 gene is deleted and the other
shows mutation at the splice site of exon 2 (Lo et al, 1995).
NPC/HK-1 also expresses a mutant p53 (Spruck et al, 1992) and a
functional pRb. HeLa cells with intact p16 was used as positive
control. Cells were grown in RPMI-1640 medium (Sigma
Chemical Company, St Louis, MO, USA) supplemented with 10%
fetal bovine serum, 1% glutamine and 1% penicillin–streptomycin
(Gibco-BRL, Grand Island, NY, USA).
The pCMV-p16 plasmid contains a full-length wild-type p16
gene inserted downstream of a CMV promotor and a neomycin
resistance selectable marker (Liggett et al, 1996; a gift from
Professor David Sidransky, Johns Hopkins University, USA). The
pCMV empty vector and the pCMV-p16 construct were trans-
fected into NPC/HK-1 cells and HeLa cells separately using
Lipofectamine reagent (Gibco-BRL, Grand Island, NY, USA)
according to manufacturer’s protocol. Transfected cells were
selected in 300 mg ml–1 G418 (Gibco-BRL, Grand Island, NY,
USA) for 4–5 weeks. Individual G418-resistant colonies were then
picked using the trypsin-soaked filter paper discs method and
expanded for further analyses.
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Polymerase chain reaction
In order to detect the presence of pCMV-p16 in the transfected
cells, the primers S9 and S13 flanking exon 1 to 3 of the p16 gene
were used to amplify the exogenous p16 cDNA sequence as
described (Lo et al, 1996).
Northern blot analysis
Total RNA was isolated from cells using TRIzol reagent (Gibco-
BRL, Grand Island, NY, USA) according to manufacturer’s
instruction. Twenty micrograms of total RNA was subjected to
electrophoresis in a 1.5% formaldehyde-containing denaturing
agarose gel followed by capillary transfer onto the Hybond-N
membrane (Amersham, Little Chalfont, UK). A full-length p16
cDNA probe was labelled with a-32P[dCTP] using the Rediprime
DNA labelling system (Amersham, Little Chalfont, UK). The blot
was hybridized with the p16 probe using Rapid Hyb buffer
(Amersham, Little Chalfont, UK). After stringency washing, the
blot was exposed to Kodak X-OMAT K film (Kodak, Rochester,
NY, USA). To normalize the levels of transcripts, the blot was
stripped and rehybridized with a glyceraldehyde 3-phosphate
dehydrogenease (GAPDH) probe.
Western blot analysis
Protein extracts were prepared according to Pagano et al (1993).
Fifty micrograms of protein were separated on a 15% sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) gel and electro-transferred onto the ECL-NC membrane
(Amersham, Little Chalfont, UK). The blots were blocked with
phosphate-buffered saline (PBS) containing 5% non-fat milk and
0.1% Tween-20 for 30 min at room temperature and treated with
rabbit anti-human p16 polyclonal antibody (1:1500; PharMingen,
San Diego, CA, USA) for 2 h at room temperature. After PBS
wash, the blots were incubated with a peroxidase-conjugated anti-
rabbit secondary antibody (1:2000; Dako, Kyoto, Japan) for 1 h.
Antigen-antibody complexes were detected by the chemilumines-
cence reagent (Amersham, Little Chalfont, UK). The expression
of Rb and cyclin D1 were detected by human monoclonal anti-
bodies of Rb (G3-245, PharMingen, San Diego, CA, USA) and
cyclin D1 (G124-326, PharMingen, San Diego, CA, USA) respec-
tively. To ensure equal loading of protein extracts, a parallel gel
was stained with Coomassie brilliant blue G250 (Sigma Chemical
Company, St Louis, MO, USA).
Cell growth and cell cycle analyses
Growth curves were constructed by cell counting over a set period
of cultivation. Cells were seeded onto a 24-well plate at 2 ´ 104
cells per well and grew in medium. A total of 300 mg ml–1 G418
were added to the medium for the transfected cells. Culture
medium was changed every 2 days and the number of cells was
counted consecutively for 7 days. Each experiment was done in
triplicate.
For flow cytometry analysis, cells (~5 ´ 106) were harvested by
trypsinization, washed with Hank’s balanced salt solution (HBSS,
Sigma Chemical Company, St Louis, MO, USA), fixed in 70%
ethanol at 4°C for 2 h, then allowed to pass through 40 mm cell
strainer (Falcon, Becton Dickinson, USA). After washing with
HBSS and adjusting the cell number to 1 ´ 106 ml–1 in HBSS
supplying with propidium iodide (50 mg ml–1), the cellular DNA
content was assessed by the System II software in a Coulter EPICS
XL MCL flow cytometer (Coulter Corporation, Miama, FL, USA)
and the cell cycle distribution data were analysed by the
Multicycle software (Phoenix Flow Systems, San Diego, CA,
USA).
Anchorage-independent growth assay
Five hundred exponentially growing cells were suspended in 2 ml
medium containing 0.35% low-melting temperature (LMT)
agarose gel (FMC, Rockland, ME, USA) and overlaid onto a layer
of 2 ml 0.6% LMT agarose gel/RPMI-1640 of each well of a
6-well plate. For the p16-transfected cells, the agarose gel/
medium containing 300 mg ml–1 G418 was used. After 3 weeks,
colonies composed of at least 16 cells were counted under an
inverted microscope.
Tumorigenicity
Balb/c nude mice of 7- to 8-week-old were used in the tumori-
genicity assay. Cells (3 ´ 106) suspended in 0.5 ml RPMI-1640
medium were injected subcutaneously into the back of each nude
mouse. Tumour growth was monitored by measuring the size of
tumours using a caliper.
RESULTS
Expression of exogenous wild-type p16
We transfected a full-length wild-type p16 expression cassette into
p16-null NPC/HK-1 cells and isolated colonies that were resistant
to G418. Polymerase chain reaction (PCR) analysis demonstrated
that six clones (N21, N24, N50, N52, N55, N104) contained the
p16 cDNA fragment, which was absent from parental cells and
cells transfected with empty vector (Figure 1A). Northern blot
analysis revealed the presence of a hybridizing band in these six
p16-transfected clones, whereas parental cells showed no
hybridization signal to the p16 probe (Figure 1B). The size of
hybridizing band of the exogenous p16 transcript was greater than
that of the endogenous p16 transcript, as revealed in HeLa and
HeLa p16-transfected cells. In addition to the band corresponded
to the endogenous p16 transcript, the larger hybridizing band of
the exogenous p16 transcript showed the same size as those bands
seen in p16-transfected NPC/HK-1 cells. After normalization with
the GAPDH signals, we found the expression levels of exogenous
p16 transcripts varied among the six p16-transfected NPC/HK-1
clones. Clone N21 expressed the highest level of p16 transcripts.
Western blot analysis was then performed to assess the expression
of p16 protein. Using a p16-specific antibody, we detected a band
of 16 kDa, characteristics of human p16, in protein extracts of the
six clones (Figure 1C). In contrast, parental and empty vector-
transfected cells showed the absence of p16 expression. Moreover,
the amount of p16 protein expressed by the p16-transfected clones
correlated with the levels of p16 transcripts. Clone N21 with the
highest expression of p16 was selected for growth and tumorigenic
assays. Expressions of the pRb and cyclin D1 proteins were
detected in both p16-transfected and parental cells (data not
shown).1124 GL Wang et al
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Effect of p16 on cell growth
To evaluate the effects of wild-type p16 expression on growth, we
examined the growth rates of the p16-transfected clone N21,
parental NPC/HK-1 cells and the vector-transfected cells by cell
proliferation assay. There was no significant difference in the
growth rate between NPC/HK-1 parental and empty vector-
transfected cells (Figure 2). However, the proliferate ability of
clone N21 was reduced and these cells grew at a slower rate. On
day 7, growth of the p16-transfected clone N21 was inhibited by
70% relative to the empty vector-transfected cells.
Flow cytometric analysis was used to assess the effect of p16 on
the cell cycle of the transfected cells (Figure 3). No significant
difference in cell cycle distributions were detected in parental and
empty vector-transfected cells. In contrast, the proportion of cells
in the S phase were reduced by more than four times in clone N21
(5.8%) when compared with those in the vector-transfected
(25.2%) and parental cells (30.5%). A corresponding increase in
cell numbers in G1 phase by 22% was also observed in N21 cells
(88.8%) comparing with those in the controls (66.3% and 66.4%).
Our results indicate that restoration of functional p16 in NPC cells
suppressed cell growth by arresting cells in the G1 phase.
Anchorage-independent growth and tumorigenicity
assays
We analysed the anchorage-independent growth transforming
potential of transfected cells by their ability to form colonies in
soft agar. The number and size of the colonies were comparable in
parental and empty vector-transfected cells. However, p16-trans-
fected clone N21 had reduced ability to grow in soft agar and the
colonies formed were much smaller (16–25 cells per colony) than
the colonies (> 200 cells per colony) formed by control cells. The
colony forming efficiency of the p16-transfected cells were about
tenfold lower when compared to those of the parental and vector-
transfected cells. These data indicate that replacement of the p16
gene reduced transforming potential in NPC cells.
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Figure 1 Expression of exogenous p16 in p16-null NPC/HK-1 cells.
(A) Demonstration of the presence of p16 cDNA fragment in transfected
cells by PCR. The expected size of the PCR product was 485 bp.
(B) Northern blot analysis of the p16 expression. Exogenous p16 transcripts
were detected in cells transfected with p16. (C) Western blot analysis of p16
protein expression. Clones that expressed exogenous p16 transcripts also
expressed the p16 protein
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Figure 2 Growth curves of NPC/HK-1 cells. The mean of cell counts from
three independent experiments were plotted. Cell growth of p16-expressing
N21 cells was reduced by 70% as compared to those of parental and empty
vector-transfected cells.
Table 1 Anchorage-independent growth in vitro and tumorigenicity in
athymic nude mice by functional restoration of p16 expression in NPC/HK-1
cells
Anchorage-independent Tumorigenicity
growth
Cell type No. of colony Nude mice Tumour volume (mm3)a
Parental 34 A 530
B 1600
Empty vector- 32 A 800
transfected B 1200
p16-transfected 3 A 0b
B0 b
aTumour size was measured 1 month post-inoculation. bTumour was
examined over a 10-month interval.
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The  p16-transfected cells as well as the parental and empty
vector-transfected cells were injected into nude mice to test for
their tumorigenicity. About 10 days post-inoculation, sizable
tumours were observed in all nude mice injected with parental or
vector-transfected cells. Table 1 depicts the growth of tumours in
nude mice, 1 month after inoculation. No tumour was observed in
the nude mice injected with the p16-expressing N21 cells over a
period of 10 months. Our results demonstrate that re-expression of
wild-type p16 in NPC cells suppressed tumorigenicity of the
malignant carcinoma cells.
DISCUSSION
It has been recognized that nasopharyngeal carcinoma, like other
solid tumours, develops and progresses as a consequence of
multiple genetic alterations (reviewed in Lo, 1997). Among these
genetic changes, p16 inactivation stands out in its high frequency
of occurrence in this cancer. As a critical tumour suppressor, p16
acts as an inhibitor of cdk4/cdk6 and can block the cyclin D1-
dependent phosphorylation of the Rb protein. Loss of p16 protein
coupled with phosphorylation of the Rb protein releases the E2F
transcription factors. This signals a cell to enter into the S phase,
and initiates uncontrolled cell proliferation. In this study, we have
demonstrated that restoration of the wild-type p16 activity in the
p16-null NPC cells caused marked growth suppression and loss of
tumorigenic potential. Our results indicate that loss of the p16
gene function is an important molecular event in the tumorigenesis
of NPC.
The well-characterized NPC cell line NPC/HK-1, which
expresses functional Rb protein and contains no wild-type p16
gene, was selected for the transfection study with pCMV-p16
plasmid. To investigate the tumour suppressive activity of p16 in
the NPC cells, the stable transfected cells consistently expressing
exogenous wild-type p16 protein were isolated. Although many
groups have reported that exogeneous p16 protein has morpho-
logical effect on several types of cancer cells (Shapiro et al, 1995;
Castellano et al, 1997), we did not observe obvious morphological
changes in the exogeneous p16-expressing NPC cells. It is likely
that the expression of the exogenous p16 did not alter the differen-
tiation in these cells. The highest level of p16 expression among
these clones was found in clone N21. Study of clone N21 showed
that replacement of the wild-type p16 gene in NPC/HK-1 resulted
in marked growth suppression. We have also performed apoptosis
analysis and found that the number of apoptotic cells did not
increase after restoration of the wild-type p16 in the NPC cells
(data not shown). The result indicated that reduction of cell growth
was not due to apoptosis induced by p16. Flow cytometry analysis
of the cell cycle in N21 showed that the expression of the exoge-
nous p16 inhibited growth by inducing a G1 arrest of the cell cycle
in these NPC cells. Our data clearly demonstrated the growth-
inhibitory role of the p16 gene in NPC. In addition, the exogenous
p16 expression in the p16-null NPC cells also inhibited the tumori-
genic potential. By anchorage-independent colony forming assay,
we found that the ability to form colonies in soft agar was highly
reduced in the cells that expressed exogenous p16. In vivo tumori-
genic study further demonstrated that these p16-expressing NPC
cells failed to grow tumours in nude mice when compared with the
control cells, for a period as long as 10 months follow-up.
Restoration of the p16 gene into other cancer cell types has been
performed previously and demonstrated similar effects on the
cancer cells. The effect of replacement of the p16 gene has been
shown to be dependent on the recipient cells. Introduction of the
p16 into glioma cells (Fueyo et al, 1996) and leukaemic cells
(Quesnel et al, 1996) have been shown to lead to cell growth inhi-
bition by inducing G1 phase accumulation in the cell cycle and
reduction in anchorage-independent growth ability. In melanoma
cells, only cell growth inhibition and morphologic changes induc-
tion had been reported (Castellano et al, 1997). The effect of
inhibiting tumorigenicity in athymic mice was also observed in the
p16-restored colon carcinoma cells (Spillare et al, 1996) and non-
small cell lung carcinoma cells (Jin et al, 1995).
Our findings have, for the first time, directly proved the critical
suppressor role of the p16 gene in the progression of NPC and
suggested its potential adequacy in gene replacement therapy. As
the molecular basis of NPC tumorigenesis is still not clear and
only a few target genes identified for the development of gene
therapy, strategies based on p16 replacement may be one of the
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Figure 3 Flow cytometric analyses of NPC/HK-1 cells. The p16-expressing
N21 cells (A) displayed a shift from S to G1 phase, yielding cell cycle
distribution of 88.8% G1, 5.8% S and 5.4% G2. By comparison, the parental
(B) and vector-transfected cells (C) showed cell cycle profiles of 66.4% and
66.4% G1; 30.5% and 25.2% S; 3.1% and 8.5% G2 respectively
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effective molecular approaches in the treatment of NPC. It has
been reported that the reintroduction of the wild-type p53 protein
in some NPC cell lines with p53 mutations showed cytotoxic
effect on the tumour cells. The high level expression of exogenous
p53 protein has led to tumour cell death, mediated through apop-
totic pathways in NPC cells (Li et al, 1997). The true usefulness of
this gene therapy strategy remains to be tested as majority of NPC
primary tumours are found to contain the wild-type p53 gene. By
mono-chromosome transfer, Cheng et al (1998) has demonstrated
that chromosome 3p21.3, frequently deleted in this cancer,
processes tumour suppressor function in NPC cells. The target
tumour suppressor gene(s) in this region has, however, not yet
been identified. Our present findings, both in vitro and in vivo,
demonstrated a significant anti-tumour effect of the p16 replace-
ment against NPC. Some reports indicated that restoration of p16
correlated with increased radiosensitivity (Miyakoshi et al, 1997).
The potential of adenovirus-mediated p16 gene transfer to NPC
cells would be a logical step for the planning of our next investiga-
tion. Since the high frequency of p16 gene inactivation in NPC, the
gene therapy strategies based on p16 replacement may be one of
the most effective molecular approaches in the treatment of NPC.
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